You can buy or sell AUPH and other stocks, options, ETFs, and crypto commission-free!
Aurinia Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of a therapeutic drug to treat autoimmune diseases particularly lupus nephritis. The company was founded by Robert Foster, Richard Glickman and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.
Victoria, British Columbia
52 Week High
52 Week Low
Seeking AlphaMay 14
Aurinia Pharmaceuticals, Inc. CEO Peter Greenleaf on Q1 2019 Results - Earnings Call Transcript
Aurinia Pharmaceuticals, Inc. (NASDAQ:AUPH) Q1 2019 Earnings Conference Call May 14, 2019 4:30 PM ET Company Participants Glenn Schulman - Investor Relations Richard Glickman - Emeritus Chairman & Chief Executive Officer Peter Greenleaf - Chief Executive Officer Dennis Bourgeault - Chief Financial Officer Neil Solomons - Chief Medical Officer Conference Call Participants Joseph Schwartz - SVB Leerink Ed Arce - H.C. Wainwright Operator Greetings, and welcome to the Aurinia Pharmaceuticals First Qu...
Seeking AlphaMay 10
Aurinia And Voclosporin In Lupus Nephritis: An Update
This was probably the best time to change leadership, because 2019 could be a transformational year for Aurinia, if the Phase 3 trial of voclosporin in lupus nephritis is successful.
Yahoo FinanceMay 9
Here’s What Hedge Funds Think About Aurinia Pharmaceuticals Inc (AUPH)
As we already know from media reports and hedge fund investor letters, many hedge funds lost money in fourth quarter, blaming macroeconomic conditions and unpredictable events that hit several sectors, with technology among them.
-$0.14 per share
-$0.14 per share